Overview

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.

Phase:

Phase 3

Details

Lead Sponsor:

SkyePharma AG

Collaborator:

Abbott

Treatments:

Fluticasone
Formoterol Fumarate
Xhance